Real-‎World Evidence Collaborative

((SLC-041)) (SLC-041) Remdesivir and Renal Outcomes in Hospitalized COVID-19 Patients Without Severe Renal Impairment: A Retrospective Cohort Study

((SLC-042)) (SLC-042) Characterizing Neuropsychiatric Adverse Events of Semaglutide Reported in FAERS: Analysis of Off-Label and On-Label Use

((SLC-043)) (SLC-043) Utilization of Real-World Evidence in Drug Approvals at the European Medicines Agency from 2020 to 2023

((SLC-044)) (SLC-044) Validity of German ICD-10-GM Diagnosis Codes for Myocardial Infarction against Chart Review of Electronic Health Records

((SLC-045)) (SLC-045) Mapping the Overall Safety Profile of Levothyroxine-Related Adverse Events: a Disproportionality Analysis on Individual Case Safety Reports Collected by the FAERS

((SLC-046)) (SLC-046) Real-World Effectiveness of Osteoporosis Medications in Reducing Fracture Rates Among Men

((SLC-047)) (SLC-047) EU-Wide Survey on Key Stakeholders’ Knowledge, Opinions and Interests on Real-World Evidence in the Regulatory Process

((SLC-048)) (SLC-048) Association between COVID-19 and thrombotic events: using Super Learner algorithm combined with doubly robust methods.

((C-203)) (C-203) Incorporation of Tokenized Real-World Data into a Phase 4 Vaccine Effectiveness Study: Assessment of Feasibility and Utility